News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
691,477 Results
Type
Article (40604)
Company Profile (289)
Press Release (650584)
Section
Business (205251)
Career Advice (2009)
Deals (35521)
Drug Delivery (85)
Drug Development (81146)
Employer Resources (168)
FDA (16150)
Job Trends (14867)
News (346523)
Policy (32561)
Tag
Academia (2601)
Alliances (49682)
Alzheimer's disease (1237)
Approvals (16079)
Artificial intelligence (132)
Bankruptcy (354)
Best Places to Work (11585)
Biotechnology (205)
Breast cancer (120)
Cancer (1087)
Cardiovascular disease (97)
Career advice (1676)
Cell therapy (233)
Clinical research (64418)
Collaboration (388)
Compensation (197)
COVID-19 (2558)
C-suite (98)
Data (1123)
Diabetes (152)
Diagnostics (6284)
Earnings (84996)
Employer resources (146)
Events (110178)
Executive appointments (311)
FDA (16686)
Funding (351)
Gene therapy (179)
GLP-1 (575)
Government (4342)
Healthcare (18760)
Infectious disease (2643)
Inflammatory bowel disease (106)
Interviews (308)
IPO (16356)
Job creations (3641)
Job search strategy (1432)
Layoffs (412)
Legal (7865)
Lung cancer (171)
Manufacturing (177)
Medical device (13205)
Medtech (13210)
Mergers & acquisitions (19238)
Metabolic disorders (401)
Neuroscience (1514)
NextGen Class of 2024 (6546)
Non-profit (4510)
Northern California (1478)
Obesity (231)
Opinion (181)
Patents (102)
People (56752)
Phase I (20034)
Phase II (28379)
Phase III (21131)
Pipeline (456)
Postmarket research (2561)
Preclinical (8611)
Radiopharmaceuticals (240)
Rare diseases (219)
Real estate (5941)
Regulatory (21622)
Research institute (2376)
Resumes & cover letters (352)
Southern California (1305)
Startups (3611)
United States (13497)
Vaccines (551)
Weight loss (167)
Date
Today (133)
Last 7 days (792)
Last 30 days (3796)
Last 365 days (35806)
2024 (32841)
2023 (40273)
2022 (51392)
2021 (55970)
2020 (54358)
2019 (46828)
2018 (35222)
2017 (32380)
2016 (31795)
2015 (37883)
2014 (31578)
2013 (26747)
2012 (28919)
2011 (29582)
2010 (27651)
Location
Africa (724)
Arizona (192)
Asia (37532)
Australia (6154)
California (3337)
Canada (1289)
China (248)
Colorado (144)
Connecticut (153)
Europe (81091)
Florida (458)
Georgia (116)
Illinois (343)
Indiana (197)
Kansas (96)
Maryland (580)
Massachusetts (2610)
Michigan (157)
Minnesota (274)
New Jersey (952)
New York (958)
North Carolina (704)
Northern California (1478)
Ohio (139)
Pennsylvania (845)
South America (1103)
Southern California (1305)
Texas (464)
Utah (90)
Washington State (363)
691,477 Results for "molecular biosystems inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lone Star Bio
Molecular Templates, Inc. Provides Interim Update
Molecular Templates, Inc. today provided an update on its clinical-stage programs.
June 3, 2024
·
7 min read
Earnings
Biogen Tops Wall Street Expectations for Leqembi, Inks Molecular Glue Deal
Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with Neomorph to discover and develop molecular glue degraders.
October 30, 2024
·
2 min read
·
Heather McKenzie
Collaboration
Novartis Inks Potential $2.2B Molecular Glue Deal With Monte Rosa
The Swiss pharma is paying $150 million upfront to gain rights to Monte Rosa’s VAV1-targeting molecular glue degraders, led by a Phase I candidate which holds therapeutic promise for immune-mediated diseases.
October 28, 2024
·
2 min read
·
Tristan Manalac
Business
Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action, today reported financial results and business updates for the first quarter of 2024.
May 15, 2024
·
6 min read
Drug Development
Molecular Templates, Inc. Provides Interim Update
Molecular Templates, Inc. today provided an update on its programs.
March 4, 2024
·
9 min read
Business
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) today reported financial results for the fourth quarter and full year ended December 31, 2023.
March 29, 2024
·
13 min read
Biotech Bay
Alveo’s Portable, Rapid Molecular Diagnostic Platform Proves Unshakable in Rigorous Ruggedness Tests
Alveo Technologies, Inc., a leader in molecular sensing and diagnostics with its proprietary technology platform, announced the results of rigorous testing that demonstrate the ruggedness of its portable molecular testing platform.
June 18, 2024
·
3 min read
Press Releases
BostonGene to Showcase AI-Driven Molecular Profiling Solutions at the Association for Molecular Pathology 2024 Annual Meeting
November 21, 2024
·
3 min read
Genetown
T2 Biosystems Announces Commercial Expansion Through Hong Kong and Macau Distributor
T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, announced the execution of a territory exclusive distribution agreement in Hong Kong and Macau.
June 25, 2024
·
4 min read
BioMidwest
GT Molecular Announces an Ultra-Sensitive RT-PCR Multiplex Panel for Eight Key KRAS G12-G13 Mutations
GT Molecular, Inc. is adding to its cancer molecular assay product line with a multi-target RT-PCR assay kit featuring robust quality control metrics and internal process controls.
June 13, 2024
·
2 min read
1 of 69,148
Next